| DP | AS + SP T1 | AS + SP T2 | AS + SP T3 |
---|---|---|---|---|
N (enrolled) | 59 | 61 | 100 | 83 |
d28 | ||||
 Successful follow-up | 53 | 57 | 97 | 78 |
 Reinfection | 0 | 0 | 0 | 0 |
 Analysed | 53 | 57 | 97 | 78 |
 Recrudescence | 0 | 0 | 1 | 0 |
 ACPR % (95 % CI) | 100 (93.2–100) | 100 (93.7–100) | 99.0 (94.4–99.8) | 100 (95.3–100) |
d42 | ||||
 Successful follow-up | 52 | 56 | 97 | 77 |
 Recurrence: reinfection | 0 | 0 | 3 | 1 |
 Recurrence: unknown genotype | 0 | 0 | 2 | 0 |
 Analysed | 52 | 56 | 92 | 76 |
 Recrudescence | 0 | 0 | 2 | 0 |
 ACPR (95 % CI) | 100 (93.1–100) | 100 (93.6–100) | 97.8 (92.4–99.4) | 100 (95.2–100) |
d56 | ||||
 Successful follow-up | 50 | 52 |  |  |
 Recurrence: reinfection | 0 | 0 |  |  |
 Recurrence: unknown genotype | 0 | 0 |  |  |
 Analysed | 50 | 52 |  |  |
 Recrudescence | 0 | 0 |  |  |
 ACPR (95 % CI) | 100 (92.9–100) | 100 (93.1–100) |  |  |